RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Supernus Pharmaceuticals Stock

Supernus Pharmaceuticals Net Income 2024

Supernus Pharmaceuticals Net Income

160.9 M USD

Ticker

SUPN

ISIN

US8684591089

WKN

A1JX3U

In 2024, Supernus Pharmaceuticals's profit amounted to 160.9 M USD, a 12,126.46% increase from the 1.32 M USD profit recorded in the previous year.

The Supernus Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2029e323.87
2028e270.36
2027e224.73
2026e131.42
2025e106.64
2024e160.9
20231.32
202260.7
202153.4
2020127
2019113.1
2018111
201757.3
201691.2
201513.9
2014-10.9
2013-92.3
2012-47.4
201150.4
2010-41.9
2009-3
2008-36.9
2007-20.7
2006-8.2

Supernus Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Supernus Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Supernus Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Supernus Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Supernus Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Supernus Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Supernus Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Supernus Pharmaceuticals’s growth potential.

Supernus Pharmaceuticals Revenue, EBIT and net profit per share

DateSupernus Pharmaceuticals RevenueSupernus Pharmaceuticals EBITSupernus Pharmaceuticals Net Income
2029e907.8 M undefined418.51 M undefined323.87 M undefined
2028e852.41 M undefined290.93 M undefined270.36 M undefined
2027e794.87 M undefined254.57 M undefined224.73 M undefined
2026e689.46 M undefined152.56 M undefined131.42 M undefined
2025e633.26 M undefined114.2 M undefined106.64 M undefined
2024e655 M undefined173.71 M undefined160.9 M undefined
2023607.52 M undefined14.92 M undefined1.32 M undefined
2022667.2 M undefined46.1 M undefined60.7 M undefined
2021579.8 M undefined108.3 M undefined53.4 M undefined
2020520.4 M undefined182.1 M undefined127 M undefined
2019392.8 M undefined148.6 M undefined113.1 M undefined
2018408.9 M undefined144.4 M undefined111 M undefined
2017302.2 M undefined99.5 M undefined57.3 M undefined
2016215 M undefined54.2 M undefined91.2 M undefined
2015147.5 M undefined20.8 M undefined13.9 M undefined
201492.7 M undefined-5.3 M undefined-10.9 M undefined
201312 M undefined-61.9 M undefined-92.3 M undefined
20121.5 M undefined-42.2 M undefined-47.4 M undefined
2011800,000 undefined-37.8 M undefined50.4 M undefined
2010100,000 undefined-40.1 M undefined-41.9 M undefined
200937.9 M undefined4 M undefined-3 M undefined
20088.9 M undefined-25.9 M undefined-36.9 M undefined
20074.2 M undefined-19 M undefined-20.7 M undefined
20066.3 M undefined-6.6 M undefined-8.2 M undefined

Supernus Pharmaceuticals stock margins

The Supernus Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Supernus Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Supernus Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Supernus Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Supernus Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Supernus Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Supernus Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Supernus Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Supernus Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Supernus Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Supernus Pharmaceuticals Margin History

Supernus Pharmaceuticals Gross marginSupernus Pharmaceuticals Profit marginSupernus Pharmaceuticals EBIT marginSupernus Pharmaceuticals Profit margin
2029e86.21 %46.1 %35.68 %
2028e86.21 %34.13 %31.72 %
2027e86.21 %32.03 %28.27 %
2026e86.21 %22.13 %19.06 %
2025e86.21 %18.03 %16.84 %
2024e86.21 %26.52 %24.56 %
202386.21 %2.46 %0.22 %
202286.93 %6.91 %9.1 %
202187.05 %18.68 %9.21 %
202089.91 %34.99 %24.4 %
201995.75 %37.83 %28.79 %
201896.23 %35.31 %27.15 %
201794.97 %32.93 %18.96 %
201694.42 %25.21 %42.42 %
201594.24 %14.1 %9.42 %
201493.74 %-5.72 %-11.76 %
201390.83 %-515.83 %-769.17 %
2012100 %-2,813.33 %-3,160 %
2011100 %-4,725 %6,300 %
201086.21 %-40,100 %-41,900 %
200986.21 %10.55 %-7.92 %
200886.21 %-291.01 %-414.61 %
200786.21 %-452.38 %-492.86 %
200686.21 %-104.76 %-130.16 %

Supernus Pharmaceuticals Aktienanalyse

What does Supernus Pharmaceuticals do?

Supernus Pharmaceuticals Inc is an American company specializing in the development, manufacturing, and marketing of pharmaceuticals. The company was founded in 2005 and is headquartered in Rockville, Maryland. Initially, Supernus Pharmaceuticals focused on developing medications for neurological disorders such as epilepsy and ADHD. However, the company has since expanded into other areas of indication such as migraine and Parkinson's disease. The top products of Supernus Pharmaceuticals are the two epilepsy medications, Oxtellar XR and Trokendi XR, both based on a patented technology called "Troxerutin Enriched Osmotic Delivery System" (TREOS). This technology allows for timed release of the active ingredient, resulting in longer duration of action and improved tolerability. Both products are approved in the United States and have proven to be effective and well-tolerated. In addition to Oxtellar XR and Trokendi XR, Supernus Pharmaceuticals has launched other products on the market, including XADAGO for the treatment of Parkinson's disease and Qudexy XR for the treatment of migraine. The company also has a number of compounds in the pipeline currently in various stages of development. The business model of Supernus Pharmaceuticals is based on the development of proprietary technologies and the marketing of novel pharmaceuticals. The company works closely with industry and scientific partners to find innovative solutions to medical challenges. For Supernus Pharmaceuticals, quality is a central component of its business model. The company adheres to strict regulatory requirements and employs modern manufacturing techniques to ensure the highest standards in pharmaceutical production. Additionally, the company maintains close relationships with healthcare providers and patient organizations to ensure that its products meet the needs of patients. Supernus Pharmaceuticals also pursues a robust growth strategy based on exploring new markets and expanding its product portfolio. The company aims to expand its pipeline and develop new technologies to improve the treatment of neurological disorders and promote patient health worldwide. Overall, Supernus Pharmaceuticals is an innovative company distinguished by its commitment to quality and focus on novel solutions in the pharmaceutical industry. The company has established itself as a leading provider of medications for neurological disorders and strives to expand its position in this growing market. Supernus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Supernus Pharmaceuticals's Profit Margins

The profit margins of Supernus Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Supernus Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Supernus Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Supernus Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Supernus Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Supernus Pharmaceuticals stock

How much profit has Supernus Pharmaceuticals made this year?

Supernus Pharmaceuticals has made 160.9 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 12,126.46% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Supernus Pharmaceuticals publish its earnings?

Supernus Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Supernus Pharmaceuticals?

The profits of Supernus Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Supernus Pharmaceuticals?

You can learn more about the earnings of Supernus Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Supernus Pharmaceuticals pay?

Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Supernus Pharmaceuticals?

The current dividend yield of Supernus Pharmaceuticals is .

When does Supernus Pharmaceuticals pay dividends?

Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Supernus Pharmaceuticals?

Supernus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Supernus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Supernus Pharmaceuticals located?

Supernus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Supernus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Supernus Pharmaceuticals from 11/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/29/2024.

When did Supernus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/29/2024.

What was the dividend of Supernus Pharmaceuticals in the year 2023?

In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Supernus Pharmaceuticals pay out the dividend?

The dividends of Supernus Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Supernus Pharmaceuticals

Our stock analysis for Supernus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Supernus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.